Primary adenocarcinoma of the urinary bladder: a report of 185 cases

EL-MEKRESH, M. M.
EL-BAZ, M. A.
ABOL-ENEIN, H.
GHONEIM, M. A.

Urology-Nephrology Centre, Mansoura, Egypt
M.M. El-Mekresh, MD, Lecturer of Urology.
M.A. El-Baz, PhD, Professor of Pathology.
H. Abol-Enein, MD, Associate Professor of Urology.
M.A. Ghoneim, MD, MD(Hon), Professor and Chief of Urology.

Accepted for publication 15 April 1998

Correspondence: Professor Dr M.A. Ghoneim, Department of Urology, Urology- Nephrology Centre, Mansoura, Egypt.

British Journal of Urology 82(2):p 206-212, August 1998.

Objective

To evaluate the outcome after the treatment of primary non-urachal vesical adenocarcinoma and to determine the significant prognostic factors.

Patients and methods

The records of 185 patients with vesical adenocarcinoma were reviewed. The pathological evaluation included the determination of pathological stage, tumour grade, presence or absence of mucin and its location, evidence of bilharzial infestation and flow-cytometric DNA analysis. The mean follow-up of the treated patients was 3.1 years. Disease-free survival was estimated and the results correlated with patient and tumour characteristics(univariate analysis). Cox's proportional hazards analysis was used to determine prognostic factors.

Results

The overall 5-year disease-free survival was 55%; only three factors had a significant impact on survival, the tumour pathological stage and grade, and lymph node involvement.

Conclusions

Radical cystectomy remains the only satisfactory treatment option for primary vesical adenocarcinoma. Tumour stage, grade and lymph node involvement are the only significant prognostic factors.